| 2026 |
Fraser, L., Wiese, M. D., Ailabouni, N., Ellett, L. K., Sirois, C., Berthelot, W., . . . Reeve, E. (2026). Patients’ attitudes towards deprescribing disease modifying anti-rheumatic drugs in rheumatoid arthritis. Patient Education and Counseling, 143(109432), 109432.
DOI |
| 2026 |
Bennett, M. G. A., Meakin, A. S., Botting-Lawford, K. J., Niu, Y., Ford, S. G., Murphy, M. P., . . . Morrison, J. L. (2026). Chronic hypoxia or MitoQ treatment in pregnancy independently alter hepatic cytochrome P450 activity in fetal sheep and 9-month-old lambs. Biochemical Pharmacology, 243(Pt 1), 13 pages.
DOI |
| 2025 |
Bennett, M. G. A., Meakin, A. S., Botting-Lawford, K. J., Niu, Y., Ford, S. G., Murphy, M. P., . . . Morrison, J. L. (2025). Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone. Pharmaceutics, 17(3), 16 pages.
DOI Scopus2 WoS2 |
| 2025 |
Maher, D., Reeve, E., & Wiese, M. (2025). Reply. Arthritis Care and Research, 77(7), 939-940.
DOI |
| 2025 |
Mangoni, A. A., Wiese, M. D., Woodman, R. J., Sotgia, S., Zinellu, A., Carru, C., . . . Tommasi, S. (2025). A controlled comparative study of the effects of methotrexate and pharmacogenetic factors on arterial blood pressure and arterial stiffness in patients with rheumatoid arthritis. Annals of Medicine, 57(1, article no. 2539311), 1-15.
DOI |
| 2025 |
Bertossa, M. R., Darby, J. R. T., Holman, S. L., Cho, S. K. S., Meakin, A. S., Lock, M. C., . . . Morrison, J. L. (2025). Fetal glucose availability: a key regulator of the metabolic, hormonal and contractility profiles of the fetal sheep heart. Journal of Physiology, 23 pages.
DOI |
| 2025 |
Modi, N. D., Li, L. X., Logan, J. M., Wiese, M. D., Abuhelwa, A. Y., McKinnon, R. A., . . . Hopkins, A. M. (2025). The state of individual participant data sharing for the highest-revenue medicines. Clinical Trials, 22(2), 170-177.
DOI |
| 2025 |
Durante, E. D., Wiese, M. D., Meakin, A. S., Hall, K. C., & Doubleday, Z. A. (2025). Reconstructing life-time reproductive histories using steroid hormones in cephalopod beaks. Limnology and Oceanography Letters, 10(2), 212-222.
DOI |
| 2025 |
Amanollahi, R., Holman, S. L., Bertossa, M. R., Meakin, A. S., Thornburg, K. L., McMillen, I. C., . . . Morrison, J. L. (2025). Ontogeny of Fetal Cardiometabolic Pathways: The Potential Role of Cortisol and Thyroid Hormones in Driving the Transition from Preterm to Near-Term Heart Development in Sheep. Journal of Cardiovascular Development and Disease, 12(2), 21 pages.
DOI Scopus6 WoS6 Europe PMC6 |
| 2025 |
Roff, A. J., Davies, A. N., Clifton, V. L., Stark, M. J., Tai, A., Robinson, J. L., . . . Gatford, K. L. (2025). Pregnancy does not affect progression of mild experimental asthma in sheep. The Journal of Physiology, 603(5), 1241-1261.
DOI Scopus2 WoS2 Europe PMC2 |
| 2025 |
Wanandy, T., Handley, S. A., Adriana Le, T. T., Lau, W. Y., Turner, M. E., & Wiese, M. D. (2025). Stability of antibiotics for use in the testing of immediate drug allergy reactions. Journal of Allergy and Clinical Immunology: In Practice, 13(2), 343-352.
DOI Scopus1 WoS1 |
| 2025 |
Amanollahi, R., Holman, S. L., Bertossa, M. R., Meakin, A. S., Clifton, V. L., Thornburg, K. L., . . . Morrison, J. L. (2025). Elevated cortisol concentration in preterm sheep fetuses impacts heart development. Experimental Physiology, online(12), 1-20.
DOI Scopus2 WoS2 Europe PMC1 |
| 2025 |
Amanollahi, R., Holman, S. L., Meakin, A. S., Padhee, M., Botting-Lawford, K. J., Zhang, S., . . . Morrison, J. L. (2025). In Vitro Embryo Culture Impacts Heart Mitochondria in Male Adolescent Sheep. Journal of Developmental Biology, 13(2), 17-1-17-20.
DOI |
| 2025 |
Chu, B., Modi, N. D., Menz, B. D., Bacchi, S., Kichenadasse, G., Paterson, C., . . . Hopkins, A. M. (2025). Generative AI’s healthcare professional role creep: a cross-sectional evaluation of publicly accessible, customised health-related GPTs. Frontiers in Public Health, 13, 1584348-1-1584348-8.
DOI Scopus2 WoS1 |
| 2025 |
Meakin, A. S., Lock, M. C., Holman, S. L., Robinson, J. L., Clifton, V. L., Roberts, C. T., . . . Morrison, J. L. (2025). Sex-specific effects of betamethasone on glucocorticoid and apoptotic signalling pathways in the sheep placenta. Journal of Physiology, 603(17), 4867-4886.
DOI |
| 2025 |
Amanollahi, R., Meakin, A. S., Holman, S. L., Clifton, V. L., Thornburg, K. L., Wiese, M. D., . . . Morrison, J. L. (2025). Antenatal betamethasone impairs markers of cardiac development and function in near-term lambs. Experimental Physiology, online, EP093025-1-EP093025-20.
DOI |
| 2025 |
Fraser, L., Ailabouni, N., Ellett, L. K., Tan, J. M., Freeman, A., Proudman, S. M., . . . Wiese, M. D. (2025). A scoping review of disease-modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice. British Journal of Clinical Pharmacology, online(12), 1-11.
DOI Europe PMC1 |
| 2025 |
Modi, N. D., Abuhelwa, A. Y., Kuderer, N. M., Li, L. X., Lyman, G. H., Koczwara, B., . . . Hopkins, A. M. (2025). Associations of commonly used concomitant medications with survival and adverse event outcomes in breast cancer. Cancer Medicine, 14(21, article no. e71320), 1-10.
DOI Europe PMC1 |
| 2025 |
Tan, J. M., Desforges, K., Chai, W. C., Proudman, S. M., Wiese, M. D., & Reeve, E. (2025). Perspectives of patients with rheumatoid arthritis towards the use of parenteral methotrexate: a qualitative study. International Journal Of Clinical Pharmacy, online, 1-12.
DOI Europe PMC1 |
| 2025 |
Meakin, A. S., Nathanielsz, P. W., Li, C., Clifton, V. L., Huber, H. F., Wiese, M. D., & Morrison, J. L. (2025). Sexually dimorphic responses in androgen metabolism and signalling in the non-human primate placenta to moderate maternal undernutrition. Biology Of Sex Differences, 16(1, article no. 93), 1-14.
DOI |
| 2024 |
Bertossa, M. R., Darby, J. R. T., Holman, S. L., Meakin, A. S., Li, C., Huber, H. F., . . . Morrison, J. L. (2024). Maternal high fat–high energy diet alters metabolic factors in the non-human primate fetal heart. Journal of Physiology, 602(17), 4251-4269.
DOI Scopus5 WoS4 Europe PMC3 |
| 2024 |
Meakin, A. S., Nathanielsz, P. W., Li, C., Clifton, V. L., Wiese, M. D., & Morrison, J. L. (2024). Maternal obesity impacts fetal liver androgen signalling in a sex-specific manner. Life Sciences, 337(122344), 122344-1-122344-9.
DOI Scopus10 WoS9 Europe PMC7 |
| 2024 |
Maher, D., Reeve, E., Hopkins, A., Tan, J. M., Tantiongco, M., Ailabouni, N., . . . Wiese, M. (2024). Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis. Arthritis Care and Research, 76(6), 871-881.
DOI Scopus7 WoS7 Europe PMC2 |
| 2024 |
Meakin, A. S., Gatford, K. L., Lien, Y. -C., Wiese, M. D., Simmons, R. A., & Morrison, J. L. (2024). Characterisation of ciclesonide metabolism in human placentae across gestation. Placenta, 154, 42-48.
DOI Scopus1 WoS1 Europe PMC1 |
| 2024 |
Tan, J. M., Upton, R. N., Foster, D. J. R., Proudman, S. M., Dhir, V., & Wiese, M. D. (2024). Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology, 90(11), 1-18.
DOI Scopus2 WoS2 Europe PMC1 |
| 2024 |
Meakin, A. S., Nathanielsz, P. W., Li, C., Huber, H. F., Clifton, V. L., Wiese, M. D., & Morrison, J. L. (2024). Maternal obesogenic diet during pregnancy and its impact on fetal hepatic function in baboons. Obesity (Silver Spring), 32(10), 1910-1922.
DOI Scopus5 WoS4 Europe PMC5 |
| 2024 |
Robinson, J. L., Roff, A. J., Hammond, S. J., Darby, J. R. T., Meakin, A. S., Holman, S. L., . . . Gatford, K. L. (2024). Betamethasone improved near-term neonatal lamb lung maturation in experimental maternal asthma. Experimental Physiology, 109(11), 1967-1979.
DOI Scopus4 WoS4 Europe PMC6 |
| 2024 |
Darby, J. R. T., Flouri, D., Cho, S. K. S., Williams, G. K., Holman, S. L., Meakin, A. S., . . . Morrison, J. L. (2024). Maternal tadalafil treatment does not increase uterine artery blood flow or oxygen delivery in the pregnant ewe. Experimental Physiology, 109(6), 980-991.
DOI Scopus2 WoS2 Europe PMC3 |
| 2024 |
Wanandy, T., Handley, S. A., Mulcahy, E., & Wiese, M. (2024). Comparative study of the commonly used protein quantitation assays on different Hymenoptera venoms: A fundamental aspect of Hymenoptera venom proteome analysis. Toxicon, 241(107685), 1-10.
DOI |
| 2024 |
Buraphaka, H., Dobutr, T., Wiese, M. D., Lopata, A. L., & Daduang, S. (2024). Structure-based epitope prediction and assessment of cross-reactivity of Myrmecia pilosula venom-specific IgE and recombinant Sol g proteins (Solenopsis geminata). Scientific Reports, 14(1), 1-13.
DOI |
| 2024 |
McGillick, E. V., Orgeig, S., Allison, B. J., Brain, K. L., Bertossa, M. R., Holman, S. L., . . . Giussani, D. A. (2024). Chronic fetal hypoxia and antenatal Vitamin C exposure differentially regulate molecular signalling in the lung of female lambs in early adulthood. Frontiers in Physiology, 15, 14 pages.
DOI Scopus2 WoS1 Europe PMC1 |
| 2024 |
Dimasi, C. G., Darby, J. R. T., Holman, S. L., Quinn, M., Meakin, A. S., Seed, M., . . . Morrison, J. L. (2024). Cardiac growth patterns and metabolism before and after birth in swine: Role of miR in proliferation, hypertrophy and metabolism. Journal of Molecular and Cellular Cardiology Plus, 9(100084), 14 pages.
DOI Scopus4 WoS4 Europe PMC4 |
| 2024 |
Dimasi, C. G., Darby, J. R. T., Cho, S. K. S., Saini, B. S., Holman, S. L., Meakin, A. S., . . . Morrison, J. L. (2024). Reduced in utero substrate supply decreases mitochondrial abundance and alters the expression of metabolic signalling molecules in the fetal sheep heart. Journal of Physiology, 602(21), 5901-5922.
DOI Scopus16 WoS17 Europe PMC15 |
| 2024 |
Mangoni, A. A., Wiese, M. D., Woodman, R. J., Sotgia, S., Zinellu, A., Carru, C., . . . Tommasi, S. (2024). Methotrexate, blood pressure and arterial function in rheumatoid arthritis: study protocol. Future Cardiology, 20(13), 671-683.
DOI |
| 2023 |
Meakin, A. S., Amirmostofian, M., Darby, J. R., Holman, S. L., Morrison, J. L., & Wiese, M. D. (2023). Characterisation of cytochrome P450 isoenzyme activity in sheep liver and placental microsomes. Placenta, 131, 82-89.
DOI Scopus3 WoS3 Europe PMC2 |
| 2023 |
Hopkins, A. M., Modi, N. D., Abuhelwa, A. Y., Kichenadasse, G., Kuderer, N. M., Lyman, G. H., . . . Sorich, M. J. (2023). Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages. JAMA Oncology, 9(12), 1621-1626.
DOI Scopus14 Europe PMC12 |
| 2023 |
Darby, J. R. T., Williams, G. K., Cho, S. K. S., Meakin, A. S., Holman, S. L., Quinn, M., . . . Morrison, J. L. (2023). Acute resveratrol exposure does not impact hemodynamics of the fetal sheep. Physiological Reports, 11(12), 12 pages.
DOI Scopus5 WoS5 Europe PMC5 |
| 2023 |
Tan, J. M., Reeve, E., Fraser, L., Proudman, S. M., & Wiese, M. D. (2023). The Barriers and Enablers to the Use of Parenteral Methotrexate in Rheumatoid Arthritis Patients: A Scoping Review. Arthritis Care and Research, 75(11), 2306-2315.
DOI Scopus2 WoS2 Europe PMC2 |
| 2023 |
Wanandy, T., Le, T. T. A., Lau, W. Y., Wiese, M. D., Heddle, R. J., & Brown, S. G. A. (2023). The development of Jack Jumper ant venom immunotherapy: our 25 years' experience. Internal medicine journal, 53(9), 1716-1721.
DOI Scopus1 WoS1 Europe PMC1 |
| 2022 |
Al Qurain, A. A., Upton, R. N., Tadros, R., Roberts, M. S., & Wiese, M. D. (2022). Population pharmacokinetic model for tramadol and O-desmethyltramadol in older patients. European Journal of Drug Metabolism and Pharmacokinetics, 47(3), 387-402.
DOI Scopus6 WoS6 Europe PMC6 |
| 2022 |
Daraghmeh, D. N., Hopkins, A. M., King, C., Abuhelwa, A. Y., Wechalekar, M. D., Proudman, S. M., . . . Wiese, M. D. (2022). Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology (Oxford, England), 62(2), 583-595.
DOI Scopus7 WoS4 Europe PMC3 |
| 2022 |
Alshabrawy, A. K., Cui, Y., Sylvester, C., Yang, D., Petito, E. S., Barratt, K. R., . . . Anderson, P. H. (2022). Therapeutic Potential of a Novel Vitamin D3 Oxime Analogue, VD1-6, with CYP24A1 Enzyme Inhibitory Activity and Negligible Vitamin D Receptor Binding. Biomolecules, 12(7), 1-14.
DOI Scopus7 WoS8 Europe PMC8 |
| 2022 |
Daraghmeh, D. N., Moghaddami, M., Bobrovskaya, L., Proudman, S. M., & Wiese, M. D. (2022). Quantitation of methotrexate polyglutamates in human whole blood, erythrocytes and leukocytes collected via venepuncture and volumetric absorptive micro-sampling: a green LC-MS/MS-based method. Analytical And Bioanalytical Chemistry, 414(20), 6029-6046.
DOI Scopus19 WoS19 Europe PMC13 |
| 2022 |
Manning Bennett, A. T., Hopkins, A. M., Sorich, M. J., Proudman, S. M., Foster, D. J. R., Abuhelwa, A. Y., & Wiese, M. D. (2022). The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials. Therapeutic Advances in Musculoskeletal Disease, 14, 1-14.
DOI Scopus16 WoS15 Europe PMC15 |
| 2022 |
Wiese, M. D., Berry, M. J., Hissaria, P., Darby, J. R. T., & Morrison, J. L. (2022). COVID-19: Can we treat the mother without harming her baby?. Journal of Developmental Origins of Health and Disease, 13(1), 9-19.
DOI Scopus6 WoS5 Europe PMC5 |
| 2022 |
Modi, N. D., Abuhelwa, A. Y., Mckinnon, R. A., Boddy, A. V., Haseloff, M., Wiese, M. D., . . . Hopkins, A. M. (2022). Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration. JAMA Oncology, 8(9), 1310-1316.
DOI Scopus17 Europe PMC17 |
| 2022 |
Tan, E., Abuhelwa, A. Y., Badaoui, S., Modi, N. D., Wiese, M. D., Mckinnon, R. A., . . . Hopkins, A. M. (2022). Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. Bladder Cancer, 8(1), 81-88.
DOI Scopus7 Europe PMC7 |
| 2022 |
Meakin, A. S., Darby, J. R. T., Holman, S. L., Wiese, M. D., & Morrison, J. L. (2022). Maternal-placental-fetal drug metabolism is altered by late gestation undernutrition in the pregnant ewe. Life Sciences, 298(article no. 120521), 1-9.
DOI Scopus15 WoS13 Europe PMC8 |
| 2022 |
Braithwaite, F. A., Noel, M., Jones, H. G., Wiese, M. D., Nania, C. G., Watson, E., & Stanton, T. R. (2022). Reframe the pain: divided attention and positive memory reframing to reduce needle pain and distress in children-a feasibility randomized controlled trial. European Journal of Pain, 26(8), 1702-1722.
DOI WoS8 Europe PMC9 |
| 2022 |
Morrison, J. L., Williams, G. K., Cho, S. K. S., Saini, B. S., Meakin, A. S., Holman, S. L., . . . Darby, J. R. T. (2022). MRI Characterization of Blood Flow and Oxygen Delivery in the Fetal Sheep whilst Exposed to Sildenafil Citrate. Neonatology, 119(6), 735-744.
DOI Scopus8 WoS8 Europe PMC8 |
| 2022 |
Wanandy, T., Mulcahy, E., Lau, W. Y., Brown, S. G. A., & Wiese, M. D. (2022). Global view on ant venom allergy: from allergenic components to clinical management. Clinical Reviews in Allergy and Immunology, 62(1), 123-144.
DOI Scopus12 Europe PMC9 |
| 2021 |
Ren, J., Darby, J. R. T., Lock, M. C., Holman, S. L., Saini, B. S., Bradshaw, E. L., . . . Morrison, J. L. (2021). Impact of maternal late gestation undernutrition on surfactant maturation, pulmonary blood flow and oxygen delivery measured by magnetic resonance imaging in the sheep fetus. Journal of Physiology, 599(20), 4705-4724.
DOI Scopus11 WoS8 Europe PMC8 |
| 2021 |
Aujla, T., Darby, J. R. T., Saini, B. S., Lock, M. C., Holman, S. L., Bradshaw, E. L., . . . Morrison, J. L. (2021). Impact of resveratrol-mediated increase in uterine artery blood flow on fetal haemodynamics, blood pressure and oxygenation in sheep. Experimental Physiology, 106(5), 1166-1180.
DOI Scopus9 WoS9 Europe PMC9 |
| 2021 |
Maher, D., Ailabouni, N., Mangoni, A. A., Wiese, M. D., & Reeve, E. (2021). Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opinion on Drug Metabolism & Toxicology, 17(1), 41-52.
DOI |
| 2021 |
Daraghmeh, D. N., King, C., & Wiese, M. D. (2021). A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis. Pharmacological Research, 173(105887), 1-9.
DOI Scopus25 WoS20 Europe PMC23 |
| 2021 |
Modi, N. D., Tan, J. Q. E., Rowland, A., Koczwara, B., Abuhelwa, A. Y., Kichenadasse, G., . . . Hopkins, A. M. (2021). The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. Npj Breast Cancer, 7(1), 30.
DOI Scopus41 Europe PMC33 |
| 2021 |
Al Qurain, A. A., Williams, D. B., Mackenzie, L., Roberts, M. S., & Wiese, M. D. (2021). Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling. Journal of Pharmaceutical and Biomedical Analysis, 203(114171), 1-8.
DOI WoS11 Europe PMC10 |
| 2021 |
Al Qurain, A. A., Gebremichael, L. G., Khan, M. S., Williams, D. B., Mackenzie, L., Phillips, C., . . . Wiese, M. D. (2021). Opioid prescribing and risk of drug-opioid interactions in older discharged patients with polypharmacy in Australia. International Journal of Clinical Pharmacy, 43(2), 365-374.
DOI Scopus9 WoS8 Europe PMC9 |
| 2021 |
Alshabrawy, A. K., Bergamin, A., Sharma, D. K., Hickey, S. M., Brooks, D. A., O'Loughlin, P., . . . Anderson, P. H. (2021). LC-MS/MS analysis of vitamin D₃ metabolites in human serum using a salting-out based liquid-liquid extraction and DAPTAD derivatization. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1173(122654), 122654-1-122654-9.
DOI Scopus14 WoS13 Europe PMC9 |
| 2021 |
Al Qurain, A. A., Upton, R., Williams, D. B., Mackenzie, L., Phillips, C., Russell, P. T., . . . Wiese, M. D. (2021). Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. European Journal Of Clinical Pharmacology, 77(9), 1357-1368.
DOI Scopus3 WoS4 Europe PMC4 |
| 2021 |
Abuhelwa, A. Y., Foster, D. J. R., Manning Bennett, A., Sorich, M. J., Proudman, S., Wiese, M. D., & Hopkins, A. M. (2021). Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis. Therapeutic Advances in Musculoskeletal Disease, 13, 1-7.
DOI Scopus2 WoS2 Europe PMC1 |
| 2021 |
Gebremichael, L. G., Suppiah, V., Wiese, M. D., Mackenzie, L., Phillips, C., Williams, D. B., & Roberts, M. S. (2021). Efficacy and safety of statins in ethnic differences: a lesson for application in Indigenous Australian patient care. Pharmacogenomics, 22(9), 553-571.
DOI Scopus1 |
| 2021 |
Deng, I., Wiese, M. D., Zhou, X. F., & Bobrovskaya, L. (2021). The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson's disease in C57BL/6 mice. NeuroToxicology, 85, 254-264.
DOI Scopus17 WoS14 Europe PMC11 |
| 2021 |
Dimasi, C. G., Lazniewska, J., Plush, S. E., Saini, B. S., Holman, S. L., Cho, S. K. S., . . . Darby, J. R. T. (2021). Redox ratio in the left ventricle of the growth restricted fetus is positively correlated with cardiac output. Journal of Biophotonics, 14(12, article no. e202100157), 1-13.
DOI Scopus16 WoS16 Europe PMC15 |
| 2021 |
McBride, G. M., Meakin, A. S., Soo, J. Y., Darby, J. R. T., Varcoe, T. J., Bradshaw, E. L., . . . Morrison, J. L. (2021). Intrauterine growth restriction alters the activity of drug metabolising enzymes in the maternal-placental-fetal unit. Life Sciences, 285(120016), 1-9.
DOI Scopus21 WoS20 Europe PMC16 |
| 2021 |
Wiese, M. D., Meakin, A. S., Varcoe, T. J., Darby, J. R. T., Sarr, O., Kiser, P., . . . Morrison, J. L. (2021). Hepatic cytochrome P450 function is reduced by life-long Western diet consumption in guinea pig independent of birth weight. Life Sciences, 287(120133), 120133-1-120133-11.
DOI Scopus8 WoS8 Europe PMC5 |
| 2021 |
Wiese, M. D., Hopkins, A. M., King, C., Wechalekar, M. D., Lee, A., Spargo, L., . . . Proudman, S. M. (2021). Precision medicine with leflunomide: consideration of DHODH haplotype and plasma teriflunomide concentration can substantially modify outcomes in patients with rheumatoid arthritis. Arthritis Care & Research, 73(7), 983-989.
DOI Scopus10 WoS7 Europe PMC6 |
| 2020 |
Reid, A. B., Wiese, M., McWilliams, L., Metcalf, R., Hall, C., Lee, A., . . . Proudman, S. M. (2020). Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. Internal Medicine Journal, 50(7), 818-822.
DOI Scopus5 WoS5 Europe PMC3 |
| 2020 |
McBride, G. M., Wiese, M. D., Soo, J. Y., Darby, J. R., Berry, M. J., Varcoe, T. J., & Morrison, J. L. (2020). The impact of intrauterine growth restriction on cytochrome P450 enzyme expression and activity. Placenta, 99, 50-62.
DOI Scopus12 WoS12 Europe PMC8 |
| 2020 |
Abuhelwa, A. Y., Hopkins, A. M., Sorich, M. J., Proudman, S., Foster, D. J. R., & Wiese, M. D. (2020). Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Scientific Reports, 10(18634), 1-9.
DOI Scopus29 WoS28 Europe PMC24 |
| 2020 |
McBride, G. M., Soo, J. Y., Varcoe, T., Morrison, J. L., & Wiese, M. D. (2020). Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes. Journal of Pharmacological and Toxicological Methods, 106, 106934-1-106934-8.
DOI Scopus7 WoS7 Europe PMC4 |
| 2020 |
Varcoe, T. J., Darby, J. R. T., Holman, S. L., Bradshaw, E. L., Kuchel, T., Vaughan, L., . . . Morrison, J. L. (2020). Fetal cardiovascular response to acute hypoxia during maternal anesthesia. Physiological reports, 8(3), e14365.
DOI Scopus14 Europe PMC12 |
| 2020 |
Al Qurain, A. A., Gebremichael, L. G., Khan, M. S., Williams, D. B., Mackenzie, L., Phillips, C., . . . Wiese, M. D. (2020). Prevalence and factors associated with analgesic prescribing in poly-medicated elderly patients. Drugs and Aging, 37(4), 291-300.
DOI Scopus22 WoS23 Europe PMC19 |
| 2020 |
Modi, N. D., Sorich, M. J., Rowland, A., Logan, J. M., McKinnon, R. A., Kichenadasse, G., . . . Hopkins, A. M. (2020). A literature review of treatment-specific clinical prediction models in patients with breast cancer. Critical Reviews in Oncology Hematology, 148(102908), 8 pages.
DOI Scopus15 WoS12 Europe PMC11 |
| 2020 |
Modi, N. D., Tan, J. Q. E., Rowland, A., Koczwara, B., Kichenadasse, G., McKinnon, R. A., . . . Hopkins, A. M. (2020). The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data. Frontiers in Oncology, 10(1130), 1130.
DOI Scopus13 Europe PMC11 |
| 2020 |
Modi, N. D., Sorich, M. J., Rowland, A., McKinnon, R. A., Koczwara, B., Wiese, M. D., & Hopkins, A. M. (2020). Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine. Clinical Breast Cancer, 20(2), e220-e228.
DOI Scopus15 Europe PMC13 |
| 2020 |
Wiese, M. D., Manning Bennett, A. T., & Abuhelwa, A. Y. (2020). Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs, 29(5), 475-482.
DOI |
| 2020 |
Soo, J. Y., Wiese, M. D., Dyson, R. M., Gray, C. L., Clarkson, A. N., Morrison, J. L., & Berry, M. J. (2020). Methamphetamine administration increases hepatic CYP1A2 but not CYP3A activity in female guinea pigs. PLoS ONE, 15(5, article no. e0233010), 1-16.
DOI |
| 2020 |
Hopkins, A. M., Menz, B. D., Wiese, M. D., Kichenadasse, G., Gurney, H., McKinnon, R. A., . . . Sorich, M. J. (2020). Nuances to precision dosing strategies of targeted cancer medicines. Pharmacology research & perspectives, 8(4, article no. e00625), 1-9.
DOI |
| 2019 |
Darby, J. R. T., Saini, B. S., Soo, J. Y., Lock, M. C., Holman, S. L., Bradshaw, E. L., . . . Morrison, J. L. (2019). Subcutaneous maternal resveratrol treatment increases uterine artery blood flow in the pregnant ewe and increases fetal but not cardiac growth. The journal of physiology, 597(20), 5063-5077.
DOI Scopus40 WoS39 Europe PMC34 |
| 2019 |
Wanandy, T., Honda Okubo, Y., Davies, N. W., Rose, H. E., Heddle, R. J., Brown, S. G. A., . . . Wiese, M. D. (2019). Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. Journal of pharmaceutical and biomedical analysis, 172, 1-8.
DOI Scopus8 WoS8 Europe PMC8 |
| 2019 |
Wabe, N., Lee, A., Wechalekar, M., McWilliams, L., Proudman, S., & Wiese, M. (2019). Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. International Journal of Clinical Practice, 73(7), 9 pages.
DOI Scopus24 WoS27 Europe PMC16 |
| 2019 |
Varcoe, T. J., Darby, J. R. T., Gatford, K. L., Holman, S. L., Cheung, P., Berry, M. J., . . . Morrison, J. L. (2019). Considerations in selecting postoperative analgesia for pregnant sheep following fetal instrumentation surgery. Animal Frontiers, 9(3), 60-67.
DOI Scopus34 WoS32 Europe PMC28 |
| 2018 |
Polasek, T. M., Tucker, G. T., Sorich, M. J., Wiese, M. D., Mohan, T., Rostami Hodjegan, A., . . . Rowland, A. (2018). Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British journal of clinical pharmacology, 84(3), 462-476.
DOI Scopus58 Europe PMC51 |
| 2018 |
Wanandy, T., Wilson, R., Gell, D., Rose, H. E., Gueven, N., Davies, N. W., . . . Wiese, M. D. (2018). Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach. Clinical and experimental allergy, 48(9), 1222-1234.
DOI Scopus16 Europe PMC13 |
| 2018 |
Baghdadi, L. R., Woodman, R. J., Shanahan, E. M., Wiese, M. D., & Mangoni, A. A. (2018). Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study. Pharmacogenomics and personalized medicine, 11, 205-210.
DOI |
| 2018 |
Soo, J. Y., Wiese, M. D., Berry, M. J., & Morrison, J. L. (2018). Does poor fetal growth influence the extent of fetal exposure to maternal medications?. Pharmacological research, 130, 74-84.
DOI |
| 2018 |
Soo, J. Y., Wiese, M. D., Berry, M. J., McMillen, I. C., & Morrison, J. L. (2018). Intrauterine growth restriction may reduce hepatic drug metabolism in the early neonatal period. Pharmacological research, 134, 68-78.
DOI |
| 2017 |
Wimmer, B. C., Cross, A. J., Jokanovic, N., Wiese, M. J., George, J., Johnell, K., . . . Bell, J. S. (2017). Clinical outcomes associated with medication regimen complexity in older people: a systematic review. Journal of the American Geriatrics Society, 65(4), 747-753.
DOI |
| 2017 |
Tait, P. A., Cheung, W. H., Wiese, M., & Staff, K. (2017). Improving community access to terminal phase medicines in Australia: Identification of the key considerations for the implementation of a 'core medicines list'. Australian journal of primary health, 23(4), 373-378.
DOI |
| 2017 |
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., . . . Sorich, M. J. (2017). Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. British journal of cancer, 117(7), 913-920.
DOI |
| 2017 |
Wanandy, T., Dwyer, H. E., McLean, L., Davies, N. W., Nichols, D., Gueven, N., . . . Wiese, M. D. (2017). Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy. Clinical and Experimental Allergy, 47(11), 1478-1490.
DOI Scopus10 Europe PMC9 |
| 2017 |
Mangoni, A. A., Baghdadi, L. R., Shanahan, E. M., Wiese, M. D., Tommasi, S., Elliot, D., & Woodman, R. J. (2017). Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Therapeutic advances in musculoskeletal disease, 9(9), 213-229.
DOI |
| 2017 |
Wabe, N., & Wiese, M. D. (2017). Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. Journal of evaluation in clinical practice, 23(3), 486-493.
DOI |
| 2017 |
Hopkins, A., Moghaddami, M., Foster, D., Proudman, S., Upton, R., & Wiese, M. (2017). Intracellular CD3⁺ T-lymphocyte teriflunomide concentration is poorly correlated with and has greater variability than unbound plasma teriflunomide concentration. Drug Metabolism Disposition, 45(1), 8-16.
DOI Scopus9 WoS9 Europe PMC8 |
| 2017 |
Hopkins, A. M., Wiese, M. D., O Doherty, C. E., & Proudman, S. M. (2017). Putting recommendations into practice: Australian rheumatologists’ opinions on leflunomide use in rheumatoid arthritis. Clinical Rheumatology, 36(4), 791-798.
DOI Scopus2 WoS2 Europe PMC2 |
| 2017 |
Maundrell, A., Lester, S., Rischmueller, M., Hill, C., Cleland, L. G., Blumbergs, P., . . . Limaye, V. (2017). The PTPN22 gene is associated with idiopathic inflammatory myopathy. Muscle and Nerve, 55(2), 270-273.
DOI Scopus4 WoS4 Europe PMC2 |
| 2017 |
Wabe, N., Lee, A., Wechalekar, M. D., McWilliams, L., Proudman, S. M., & Wiese, M. (2017). Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. Rheumatology international, 37(6), 897-904.
DOI Scopus23 WoS25 Europe PMC21 |
| 2017 |
Wojciechowski, J., Upton, R. N., Mould, D. R., Wiese, M. D., & Foster, D. J. R. (2017). Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies. AAPS Journal, 19(4), 1136-1147.
DOI Scopus32 WoS33 Europe PMC26 |
| 2017 |
Rowland, A., Van Dyk, M., Mangoni, A. A., Miners, J. O., McKinnon, R. A., Wiese, M. D., . . . Sorich, M. J. (2017). Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert opinion on drug metabolism and toxicology, 13(1), 31-49.
DOI Scopus64 Europe PMC46 |
| 2017 |
Wabe, N., Wojciechowski, J., Wechalekar, M. D., Cleland, L. G., McWilliams, L., Lee, A., . . . Wiese, M. D. (2017). Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. International Journal of Rheumatic Diseases, 20(10), 1447-1456.
DOI Scopus13 WoS13 Europe PMC9 |
| 2017 |
Dias, M., Sorich, M., Rowland, A., Wiese, M., & McKinnon, R. (2017). The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?. Pharmaceutical Research, 34(8), 1544-1550.
DOI Scopus18 WoS19 Europe PMC15 |
| 2017 |
Hopkins, A., Vitry, A., O'Doherty, C., Proudman, S., & Wiese, M. (2017). Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide. International Journal of Rheumatic Diseases, 20(11), 1795-1797.
DOI Scopus1 WoS1 Europe PMC1 |
| 2017 |
Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., Mcwilliams, L., Lee, A., . . . Wiese, M. (2017). Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 20(5), 576-583.
DOI Scopus7 WoS7 Europe PMC7 |
| 2016 |
Wojciechowski, J., Wiese, M., Proudman, S., Foster, D., & Upton, R. (2016). A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. British Journal of Clinical Pharmacology, 81(6), 1046-1057.
DOI Europe PMC1 |
| 2016 |
Hopkins, A., Proudman, S., Vitry, A., Sorich, M., Cleland, L., & Wiese, M. (2016). Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. Medical Journal of Australia, 204(2), 64-68.e1.
DOI Scopus16 WoS14 Europe PMC9 |
| 2016 |
Hopkins, A., Wiese, M., Proudman, S., O'Doherty, C., Upton, R., & Foster, D. (2016). Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. British Journal of Clinical Pharmacology, 81(1), 113-123.
DOI Scopus20 WoS14 Europe PMC13 |
| 2016 |
Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. (2016). Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?. International Journal of Clinical Practice, 70(4), 340-350.
DOI Scopus2 WoS2 Europe PMC1 |
| 2016 |
Lester, S., Hewitt, A., Ruediger, C., Bradbury, L., De Smit, E., Wiese, M., . . . Hill, C. (2016). PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis. RMD Open, 2(1), e000246-1-e000246-3.
DOI Scopus8 WoS10 Europe PMC5 |
| 2016 |
Rowland, A., Karapetis, C. S., Mangoni, A. A., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., & Sorich, M. J. (2016). Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. Translational Cancer Research, 5(S1), S31-S34.
DOI Scopus1 |
| 2016 |
Tao, B., Bernardo, K., Eldi, P., Chegeni, N., Wiese, M., Colella, A., . . . Chataway, T. (2016). Extended boiling of peanut progressively reduces IgE allergenicity while retaining T cell reactivity. Clinical and Experimental Allergy, 46(7), 1004-1014.
DOI Scopus47 WoS41 Europe PMC27 |
| 2016 |
Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. (2016). Effect of adherence to protocolized targeted intensifications of disease-modifying antirheumatic drugs on treatment outcomes in rheumatoid arthritis: results from an Australian early arthritis cohort. The Journal of Rheumatology, 43(9), 1643-1649.
DOI Scopus12 WoS11 Europe PMC8 |
| 2016 |
Polasek, T. M., Ambler, K., Scott, H. S., Sorich, M. J., Kaub, P. A., Rowland, A., . . . Kichenadasse, G. (2016). Targeted pharmacotherapy after somatic cancer mutation screening. F1000Research, 5(1551), 1-8.
DOI Scopus11 Europe PMC7 |
| 2016 |
Rowland, A., Dias, M., Wiese, M., Kichenadasse, G., McKinnon, R., Karapetis, C., & Sorich, M. (2016). Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. European Journal of Cancer, 55, 122-130.
DOI Scopus38 WoS35 Europe PMC30 |
| 2016 |
Polasek, T. M., Ambler, K., Scott, H. S., Sorich, M. J., Kaub, P. A., Rowland, A., . . . Kichenadasse, G. (2016). Targeted pharmacotherapy after somatic cancer mutation screening [version 1; referees: 1 approved]. F1000Research, 5, 1551.
DOI Scopus1 |
| 2016 |
Wimmer, B. C., Bell, J. S., Fastbom, J., Wiese, M. D., & Johnell, K. (2016). Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study. Annals of Pharmacotherapy, 50(2), 89-95.
DOI |
| 2016 |
Wimmer, B. C., Bell, J. S., Fastbom, J., Wiese, M. D., & Johnell, K. (2016). Medication regimen complexity and number of medications as factors associated with unplanned hospitalizations in older people: a population-based cohort study. Journals of gerontology - series A : biological sciences and medical sciences, 71(6), 831-837.
DOI |
| 2016 |
Shahnam, A., Ridha, Z., Wiese, M. D., Kichenadasse, G., & Sorich, M. J. (2016). Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. Pharmacogenomics, 17(5), 1725-1732.
DOI |
| 2015 |
Polasek, T. M., Rowland, A., Wiese, M. D., & Sorich, M. J. (2015). Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. Therapeutic Advances in Drug Safety, 6(5), 186-188.
DOI |
| 2015 |
Reeve, E., Wiese, M. D., & Mangoni, A. A. (2015). Alterations in drug disposition in older adults. Expert opinion on drug metabolism & toxicology, 11(4), 491-508.
DOI Scopus94 Europe PMC66 |
| 2015 |
Rowland, A., Dias, M., Wiese, M., Kichenadasse, G., McKinnon, R., Karapetis, C., & Sorich, M. (2015). Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. British Journal of Cancer, 112(12), 1888-1894.
DOI Scopus276 WoS249 Europe PMC216 |
| 2015 |
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., Mckinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015). Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'. British Journal of Cancer, 113(11), 1635.
DOI Scopus8 WoS3 Europe PMC3 |
| 2015 |
Hopkins, A. M., Foster, D., Wiese, M., & Upton, R. (2015). Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide - Should Consideration Be Given to Cannalicular Efflux Transporters?. CPT: Pharmacometrics and Systems Pharmacology, 4(10), 564.
DOI |
| 2015 |
Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. D. (2015). Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy. ARTHRITIS & RHEUMATOLOGY, 67, 2 pages. |
| 2015 |
Hopkins, A., Wiese, M., Proudman, S., O'Doherty, C., Foster, D., & Upton, R. (2015). Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients. CPT: Pharmacometrics and Systems Pharmacology, 4(6), 362-371.
DOI Scopus16 WoS15 Europe PMC11 |
| 2015 |
Reeve, E., Andrews, J., Wiese, M., Hendrix, I., Roberts, M., & Shakib, S. (2015). Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors. Annals of Pharmacotherapy, 49(1), 29-38.
DOI Scopus76 WoS58 Europe PMC54 |
| 2015 |
Mohamed, H., Sorich, M., Kowalski, S., McKinnon, R., Proudman, S., Cleland, L., & Wiese, M. (2015). The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies - a systematic review. European Journal of Clinical Pharmacology, 71(4), 411-423.
DOI Scopus27 WoS25 Europe PMC19 |
| 2015 |
Wabe, N., Sorich, M., Wechalekar, M., Cleland, L., McWilliams, L., Lee, A., . . . Wiese, M. (2015). Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. Arthritis Research and Therapy, 17(1), 48-1-48-14.
DOI Scopus23 WoS23 Europe PMC19 |
| 2015 |
Wojciechowski, J., Wiese, M., Proudman, S., Foster, D., & Upton, R. (2015). A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. British journal of clinical pharmacology, 79(5), 777-788.
DOI Scopus6 WoS5 Europe PMC6 |
| 2015 |
Wimmer, B. C., Johnell, K., Fastbom, J., Wiese, M. D., & Bell, S. J. (2015). Factors associated with medication regimen complexity in older people: a cross-sectional population-based study. European journal of clinical pharmacology, 71(9), 1099-1108.
DOI |
| 2015 |
Wanandy, T., Gueven, N., Davies, N. W., Brown, S. G. A., & Wiese, M. (2015). Pilosulins: a review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula. Toxicon, 98, 54-61.
DOI Scopus36 Europe PMC25 |
| 2015 |
Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2015). Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Annals of oncology, 26(1), 13-21.
DOI |
| 2014 |
Reeve, E., & Wiese, M. D. (2014). Benefits of deprescribing on patients' adherence to medications. International journal of clinical pharmacy, 36(1), 26-29.
DOI |
| 2014 |
Sorich, M. J., Wiese, M. D., & Pekarsky, B. A. K. (2014). Cost-effectiveness of genotyping to guide treatment. Pharmacogenomics, 15(6), 727-729.
DOI |
| 2014 |
Reeve, E., Shakib, S., Hendrix, I., Roberts, M., & Wiese, M. (2014). The benefits and harms of deprescribing. Medical Journal of Australia, 201(7), 386-389.
DOI Scopus92 WoS70 Europe PMC60 |
| 2014 |
Russo, P. A. J., Banovic, T., Wiese, M. D., Whyte, A. F., & Smith, W. B. (2014). Systemic allergy to EDTA in local anesthetic and radiocontrast media. Journal of allergy and clinical immunology: in practice, 2(2), 225-229.
DOI Scopus21 WoS23 Europe PMC15 |
| 2014 |
Hopkins, A., O'Doherty, C., Foster, D., Suppiah, V., Upton, R., Spargo, L., . . . Wiese, M. (2014). The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity. Journal of Clinical Pharmacy and Therapeutics, 39(5), 555-560.
DOI Scopus6 WoS5 Europe PMC4 |
| 2014 |
Hopkins, A. M., O'Doherty, C. E., Foster, D. J. R., Upton, R. N., Proudman, S. M., & Wiese, M. D. (2014). Individualization of leflunomide dosing in rheumatoid arthritis patients. Personalized Medicine, 11(4), 449-461.
DOI Scopus7 WoS8 Europe PMC5 |
| 2014 |
Wiese, M., Alotaibi, N., O'Doherty, C., Sorich, M., Suppiah, V., Cleland, L., & Proudman, S. (2014). Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics Journal, 14(4), 350-355.
DOI Scopus24 WoS21 Europe PMC21 |
| 2014 |
Wimmer, B., Dent, E., Bell, J., Wiese, M., Chapman, I., Johnell, K., & Visvanathan, R. (2014). Medication regimen complexity and unplanned hospital readmissions in older people. Annals of Pharmacotherapy, 48(9), 1120-1128.
DOI Scopus58 WoS53 Europe PMC49 |
| 2014 |
Wimmer, B., Dent, E., Visvanathan, R., Wiese, M., Johnell, K., Chapman, I., & Bell, J. (2014). Polypharmacy and medication regimen complexity as factors associated with hospital discharge destination among older people: a prospective cohort study. Drugs and Aging, 31(8), 623-630.
DOI Scopus44 WoS44 Europe PMC33 |
| 2014 |
Reeve, E., Shakib, S., Hendrix, I., Roberts, M., & Wiese, M. (2014). Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. British Journal of Clinical Pharmacology, 78(4), 738-747.
DOI Scopus302 WoS277 Europe PMC224 |
| 2014 |
Wiese, M. D., Suppiah, V., & O'Doherty, C. (2014). Metabolic and safety issues for multiple sclerosis pharmacotherapy: opportunities for personalised medicine. Expert opinion on drug metabolism & toxicology, 10(8), 1145-1159.
DOI Scopus3 WoS2 Europe PMC1 |
| 2014 |
Stone, S. F., Phillips, E. J., Wiese, M. D., Heddle, R. J., & Brown, S. G. A. (2014). Immediate-type hypersensitivity drug reactions. British journal of clinical pharmacology, 78(1), 1-13.
DOI Scopus53 WoS37 Europe PMC32 |
| 2014 |
Sorich, M. J., Rowland, A., McKinnon, R. A., & Wiese, M. D. (2014). CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with Clopidogrel : a meta-analysis. Circulation : Cardiovascular genetics, 7(6), 895-902.
DOI |
| 2013 |
Sorich, M. J., Wiese, M. D., O'Shea, R. L., & Pekarsky, B. (2013). Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. Pharmacoeconomics, 31(5), 377-391.
DOI |
| 2013 |
Bell, J. S., Johnell, K., Wimmer, B. C., & Wiese, M. D. (2013). Multidose drug dispensing and optimising drug use in older people. Age and Ageing, 42(5), 556-558.
DOI |
| 2013 |
Wahab, I. A., Pratt, N. L., Wiese, M. D., Kalisch, L. M., & Roughead, E. E. (2013). The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiology and drug safety, 22(5), 496-502.
DOI Scopus69 WoS62 Europe PMC59 |
| 2013 |
Reeve, E., Wiese, M., Hendrix, I., Roberts, M., & Shakib, S. (2013). People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. Journal of the American Geriatrics Society, 61(9), 1508-1514.
DOI Scopus197 WoS173 Europe PMC153 |
| 2013 |
Reeve, E., To, J., Hendrix, I., Shakib, S., Roberts, M., & Wiese, M. (2013). Patient barriers to and enablers of deprescribing: a systematic review. Drugs and Aging, 30(10), 793-807.
DOI Scopus415 WoS393 Europe PMC344 |
| 2013 |
Reeve, E., Shakib, S., Hendrix, I., Roberts, M., & Wiese, M. (2013). Development and validation of the patients' attitudes towards deprescribing (PATD) questionnaire. International Journal of Clinical Pharmacy, 35(1), 51-56.
DOI Scopus94 WoS89 Europe PMC83 |
| 2013 |
Sorich, M., Horowitz, J., Sorich, W., Wiese, M., Pekarsky, B., & Karnon, J. (2013). Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. Pharmagenomics, 14(16), 2013-2021.
DOI Scopus33 WoS31 Europe PMC25 |
| 2013 |
Russo, P. A. J., Wiese, M. D., Smith, M. D., Ahern, M. J., Barbara, J. A., & Shanahan, E. M. (2013). Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. The annals of pharmacotherapy, 47(3), 15-27.
DOI Scopus14 WoS11 Europe PMC12 |
| 2013 |
Sorich, M. J., Polasek, T. M., & Wiese, M. D. (2013). Challenges and limitations in the interpretation of systematic reviews : making sense of clopidogrel and CYP2C19 pharmacogenetics. Clinical pharmacology and therapeutics, 94(3), 376-382.
DOI |
| 2013 |
Wiese, M. D., Rowland, A., Polasek, T. M., Sorich, M. J., & O'Doherty, C. (2013). Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert opinion on drug metabolism & toxicology, 9(8), 1025-1035.
DOI |
| 2013 |
Polasek, T. M., Patel, F., Jensen, B. P., Sorich, M. J., Wiese, M. D., & Doogue, M. P. (2013). Predicted metabolic drug clearance with increasing adult age. British journal of clinical pharmacology, 75(4), 1019-1028.
DOI |
| 2012 |
Alene, M., Wiese, M. D., Angamo, M. T., Bajorek, B. V., Yesuf, E. A., & Wabe, N. T. (2012). Adherence to medication for the treatment of psychosis : rates and risk factors in an Ethiopian population. BMC clinical pharmacology, 12(1), 1-9.
DOI |
| 2012 |
Wiese, M., Schnabl, M., O'Doherty, C., Spargo, L., Sorich, M., Cleland, L., & Proudman, S. (2012). Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Research & Therapy, 14(4), 1-9.
DOI Scopus41 WoS37 Europe PMC32 |
| 2012 |
O'Doherty, C., Schnabl, M., Spargo, L., Cleland, L., James, M., Proudman, S., & Wiese, M. (2012). Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmagenomics, 13(12), 1427-1434.
DOI Scopus24 WoS24 Europe PMC23 |
| 2012 |
Wiese, M., Sluggett, J., Wilson, C., Reuter, S., Turner, S., & Evans, A. (2012). Perceived and actual paracetamol dosing in overweight and obese children. EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 19(5), 438-442.
DOI Scopus2 WoS2 |
| 2012 |
Chaudhry, T., Hissaria, P., Wiese, M., Heddle, R., Kette, F., & Smith, W. B. (2012). Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis. Internal medicine journal, 42(6), 665-671.
DOI Scopus35 WoS31 Europe PMC22 |
| 2012 |
Brown, S. G. A., Wiese, M. D., van, E. P. E., Stone, S. F., Chuter, C. L., Gunner, J., . . . Heddle, R. J. (2012). Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. Journal of allergy and clinical immunology, 130(1), 162-168.
DOI Scopus53 Europe PMC33 |
| 2012 |
Reeve, E., & Wiese, M. D. (2012). Difficulties reducing inappropriate prescribing of proton pump inhibitors in the elderly. Drugs & aging, 29(11), 925-926.
DOI |
| 2012 |
Sorich, M. J., Polasek, T. M., & Wiese, M. D. (2012). Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thrombosis and haemostasis, 108(1), 199-200.
DOI |
| 2011 |
Rakhila, H., Rozek, T., Hopkins, A., Proudman, S., Cleland, L., James, M., & Wiese, M. (2011). Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 55(2), 325-331.
DOI Scopus49 WoS44 Europe PMC26 |
| 2011 |
Wiese, M. D., & Shahnam, H. (2011). Current status on drug allergy. The Australian journal of pharmacy, 92(1098), 84-88. |
| 2011 |
van Eeden, P. E., Wiese, M. D., Aulfrey, S., Hales, B. J., Stone, S. F., & Brown, S. G. A. (2011). Using time-resolved fluorescence to measure serum venom-specific IgE and IgG. PLoS one, 6(1 article no. 16741), e16741.
DOI Scopus12 Europe PMC11 |
| 2011 |
Wiese, M. D., Davies, N. W., Chataway, T. K., Milne, R. W., Brown, S. G. A., & Heddle, R. J. (2011). Stability of Myrmecia pilosula (Jack Jumper) ant venom for use in immunotherapy. Journal of pharmaceutical and biomedical analysis, 54(2), 303-310.
DOI Scopus12 Europe PMC10 |
| 2011 |
Brown, S. G. A., Van Eeden, P. E., Wiese, M. D., Mullins, R. J., Solley, G. O., Puy, R., . . . Heddle, R. (2011). Causes of ant sting anaphylaxis in Australia: the Australian ant venom allergy study. Medical journal of Australia, 195(2), 69-73.
DOI Scopus40 Europe PMC21 |
| 2008 |
Wiese, M. D., Milne, R. W., Davies, N., Chataway, T., Brown, S., & Heddle, R. (2008). Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine. Journal of pharmaceutical and biomedical analysis, 46(1), 58-65.
DOI Scopus17 Europe PMC13 |
| 2008 |
Inagaki, H., Akagi, M., Imai, H. T., Taylor, R., Wiese, M. D., Davies, N., & Kubo, T. (2008). Pilosulin 5, a novel histamine-releasing peptide of the Australian ant, Myrmecia pilosula (Jack Jumper Ant). Archives of Biochemistry and Biophysics, 477(2), 411-416.
DOI |
| 2007 |
Wiese, M. D., Brown, S., Chataway, T., Davies, N., Milne, R. W., Aulfrey, S., & Heddle, R. (2007). Myrmecia pilosula (Jack Jumper) ant venom : identification of allergens and revised nomenclature. Allergy: European journal of allergy and immunology, 62(4), 437-443.
DOI Scopus43 Europe PMC35 |
| 2006 |
Wiese, M. D., Chataway, T., Davies, N., Milne, R. W., Brown, S., Gai, W. P., & Heddle, R. (2006). Proteomic analysis of myrmecia pilosula (jack jumper) ant venom. Toxicon, 47(2), 208-217.
DOI Scopus36 Europe PMC32 |
| 2005 |
Brown, S. G. A., Heddle, R. J., Wiese, M. D., Blackman, K. E., & Golden, D. B. K. (2005). Efficacy of ant venom immunotherapy and whole body extracts [5] (multiple letters). Journal of Allergy and Clinical Immunology, 116(2), 464-465.
DOI Scopus4 Europe PMC2 |
| 2003 |
Brown, S., Wiese, M. D., Blackman, K., & Heddle, R. (2003). Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. The Lancet, 361(9362), 1001-1006.
DOI Scopus131 Europe PMC80 |
